SSWM
SRPT icon

Smith Salley Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Smith Salley Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,308
Closed -$466K – 264
2025
Q1 		$466K Hold
7,308
– – 0.03% 174
2024
Q4 		$889K Buy
+7,308
New +$896K 0.06% 147

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Smith Salley Wealth Management's SRPT Position: Q2 2025 in Review

Smith Salley Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 7,308 shares — an estimated $466K sold.

Smith Salley Wealth Management first reported a position in SRPT in Q4 2024 and held it in 2 quarters. The position peaked at $889K in Q4 2024. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Smith Salley Wealth Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Smith Salley Wealth Management sold 7,308 Sarepta Therapeutics shares in Q2 2025, an estimated $466K.
  • Smith Salley Wealth Management first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 2 quarters.
  • Smith Salley Wealth Management's Sarepta Therapeutics position peaked at $889K in Q4 2024.
  • 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Smith Salley Wealth Management's 13F filing for Q2 2025, filed 17 Jul 2025.